We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FDA cited sterile drugmaker Nanobots Healthcare in Houston, Texas in a lengthy Form 483 for deficiencies with testing, sterility, certification and equipment calibration. Read More
A group of more than 30 consumer, health and trade organizations urged three dozen countries — including the U.S. — to allow imports of drugs manufactured under government-issued patent exemptions during the COVID-19 crisis. Read More
The Drug Enforcement Administration (DEA) is allowing increased production and importation of some controlled medicines to address the surge in demand for drugs needed for COVID-19 patients on ventilators. Read More
The FDA hit Pennsauken, New Jersey drugmaker Cetylite Industries with a Form 483 for multiple GMP failures and the lack of annual product reviews. Read More
The World Health Organization’s director-general has endorsed the voluntary sharing of patent rights and pooling of data to help develop COVID-19 drugs. Read More